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Abstract The Myc promoter-binding protein-1 (MBP-1) is a
37^38 kDa protein that binds to the c-myc P2 promoter and
negatively regulates transcription of the protooncogene. MBP-1
cDNA shares 97% similarity with the cDNA encoding the
glycolytic enzyme K-enolase and both genes have been mapped to
the same region of human chromosome 1, suggesting the
hypothesis that the two proteins might be encoded by the same
gene. We show here data indicating that a 37 kDa protein is
alternatively translated from the full-length K-enolase mRNA.
This shorter form of K-enolase is able to bind the MBP-1
consensus sequence and to downregulate expression of a
luciferase reporter gene under the control of the c-myc P2
promoter. Furthermore, using K-enolase/green fluorescent pro-
tein chimeras in transfection experiments we show that, while the
48 kDa K-enolase mainly has a cytoplasmic localization, the
37 kDa K-enolase is preferentially localized in the cell nuclei. The
finding that a transcriptional repressor of the c-myc oncogene is
an alternatively translated product of the ENO1 gene, which
maps to a region of human chromosome 1 frequently deleted in
human cancers, makes ENO1 a potential candidate for tumor
suppressor.
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1. Introduction
The c-myc protooncogene is a critical factor in the control
of cell proliferation, di¡erentiation and apoptosis [1^3]. Per-
turbation of c-myc gene expression occurs in di¡erent tumors
in a variety of species and this is thought to be a crucial step
in tumorigenesis [2,4]. The pivotal role of c-myc in regulating
cell proliferation and cell death is consistent with the obser-
vations that its expression is tightly controlled in normal cells
and downregulation at both mRNA and protein level is a
prerequisite for di¡erentiation in many cell types [2]. The ex-
pression of the c-myc gene is extremely complex and is con-
trolled by several mechanisms, including changes in transcrip-
tion initiation and transcript elongation, as well as stability,
turnover and translational state of mRNA [2]. At the level of
transcription initiation multiple promoters, termed P0, P1, P2,
and P3, have been characterized, although in normal and
transformed cells the majority of mRNAs initiate at the P2
promoter [5]. Several cis-acting sequences have been identi¢ed
both 5P and 3P to the major P2 transcription start site [5].
These sequences, although a few of them are located quite
distant from the P2 promoter, regulate transcription initiation
from P2 and include binding sites for many known transcrip-
tion factors (reviewed in [2]). Some of these factors are ex-
pressed in a cell- and tissue-speci¢c manner and some of them,
such as Fos/Jun, Blimp-1, CTCF [5] and ZF87/MAZ [6], func-
tion as repressors of c-myc transcription from the P2 pro-
moter. The Myc promoter-binding protein-1 (MBP-1) has
been identi¢ed as a 37^38 kDa protein which binds just 5P
to the P2 TATA motif and negatively regulates both human
and mouse c-myc promoter activities [7,8]. It has been shown
that MBP-1 and TBP (TATA-binding protein) both bind to
the minor groove of the c-myc P2 promoter [9], suggesting
that MBP-1 may negatively regulate c-myc transcription by
preventing the formation of a transcription initiation complex.
It has been reported that MBP-1 is ubiquitously expressed
and a single transcript has been detected in HeLa as well as
in other cell lines [7]. MBP-1 cDNA shares 97% similarity
with the cDNA encoding the K-isoform of the glycolytic en-
zyme enolase both in the coding region and in the 3P-untrans-
lated sequence [10]. The enzyme is responsible for the inter-
conversion of 2-phosphoglycerate to phosphoenolpyruvate in
the glycolytic pathway and it is present in mammalian tissues
as three isoforms, K- L- and Q-enolase, that are encoded by
three distinct genes [11^13]. The presence of two single-base
insertions in the MBP-1 sequence results in a shift in the read-
ing frame as compared to the K-enolase coding region [7,14].
These insertions a¡ect the amino-terminal portion of the
MBP-1 protein whereas the amino acid sequence of the car-
boxy-terminal region is identical to the corresponding K-eno-
lase sequence (GDB accessions: M14328 and M55914). These
observations and the chromosomal location of MBP-1 on
human chromosome 1p36 [14,15], in close proximity of
ENO1, the gene encoding K-enolase, strongly suggest that
MBP-1 and K-enolase could be encoded by the same gene.
Furthermore, the observation that no alternatively spliced
forms or variant transcripts of the ENO1 gene have been
detected in several cell lines and tissues [11,16] suggests that
K-enolase and MBP-1 could arise from the same transcript.
We show here that a single human K-enolase transcript en-
codes two proteins of 48 and 37 kDa that are targeted to
di¡erent cellular compartments, based on initiation of synthe-
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sis at alternative in-frame AUGs. The 37 kDa alternatively
translated isoform, which preferentially localizes in the cell
nucleus, shares with MBP-1 the capability to downregulate
transcription from the c-myc P2 promoter indicating an addi-
tional functional role for K-enolase.
2. Materials and methods
2.1. Preparation of nuclear extracts and electrophoretic mobility shift
assays (EMSAs)
Nuclear extracts were prepared from HeLa cells as previously de-
scribed [17]. The following double-stranded oligonucleotides were
used as probe and competitor in EMSAs: MP2 (5P-AGGGATC-
GCGCTGAGTATAAAAGCCGGTTTTCGGGG-3P) containing the
binding site for MBP-1 [7], and BEE-1 (5P-AGCTGTTCTGAGT-
GGGGGAGGGGGCTGCGCCTGC-3P) containing an unrelated
consensus. EMSAs were performed by incubating end-labeled probes
(0.1 ng, about 40 000 cpm) with 5 Wg of nuclear extracts and 2 Wg of
poly(dI-dC) (Pharmacia) in 15 mM HEPES (pH 7.9), 40 mM KCl,
1 mM EDTA, 0.5 mM dithiothreitol, 10% glycerol, 5 mM spermidine
(Sigma) as previously described [17]. When the GST^ENO1 protein
was used, the binding reaction mixtures contained 0.5 Wg of a⁄nity-
puri¢ed GST^ENO1, 0.5 Wg of poly(dI-dC) and 1 Wg of bovine serum
albumin. DNA^protein complexes were resolved by electrophoresis on
a 5% polyacrylamide gel in 25 mM TBE (25 mM Tris pH 8.3, 20 mM
boric acid, 0.5 mM EDTA) and visualized by autoradiography. For
antibody interference, EMSAs were performed under the conditions
described above except for the addition to the reaction mixture of 1 Wl
rabbit anti-K-enolase antiserum [10] or 1 Wl of rabbit pre-immune
serum.
2.2. Construction of luciferase reporter expression vectors and plasmids
expressing wild-type and mutant K-enolase
The pGL-cmp luciferase reporter expression vector was obtained by
blunt-end ligation into the SmaI site of the pGL3-basic vector (Prom-
ega) of a 860 bp PvuII/PvuII fragment derived from plasmid pMC41,
which contains the human c-myc gene [18]. This fragment corresponds
to region 3350/+510, relative to the P1 transcription start site of the
c-myc gene, and it has been shown to drive e⁄cient transcription of
reporter genes in several cell lines [19]. The pRCENO1 expression
vector was obtained by cloning into the cytomegalovirus promoter-
directed expression vector pRC/CMV (Invitrogen) a 1740 bp HindIII/
XbaI fragment of the human K-enolase cDNA, containing the entire
coding region and most of the 3P-untranslated region of the human K-
enolase cDNA [10]. The pRCENO2 expression vector was obtained
by inserting into the KpnI and EcoRV sites of the pRC/CMV vector a
1790 bp KpnI/NdeI-¢lled fragment of the human Q-enolase cDNA,
containing the entire coding region and part of the 3P-untranslated
region [20]. To generate the pRCENO1-97 expression vector a frag-
ment of 1278 bp was obtained by PCR from the K-enolase cDNA
using the oligonucleotide primers PSA-97 (5P-CCCAAGCTTAC-
CATGGATGGAACAGAAAAT-3P) and revB5 (5P-CAGGAAA-
CAGCTATGACCATGA-3P), the restriction site in the primer is
underlined. After ampli¢cation with Pfu polymerase (Stratagene), in
order to minimize mutations [21], the ampli¢ed fragment was digested
with HindIII and XbaI and ligated into the pRC/CMV vector. To
generate green £uorescent protein (GFP)-fused protein two DNA
fragments were obtained by PCR from the pRCENO1 and pRCE-
NO1-97 plasmids using oligonucleotide primers T7-P (5P-TGTAA-
TACGACTCACTATAG-3P) and End-1 (5P-CGGGATCCTTGGC-
CAAGGGGTT-3P) in the condition described above. The ampli¢ed
fragments were digested with HindIII and BamHI and ligated into the
pEGFP-N1 vector (Clontech) to obtain the pENO1-GFP and the
pENO1-97-GFP expression vectors, respectively. The nucleotide se-
quence of the K-enolase DNA fragments generated by PCR was con-
¢rmed by sequencing.
2.3. Protein expression in bacteria and by in vitro transcription and
translation
A 1.35 kb BglII^XhoI fragment encoding amino acids 10^433 was
isolated from the K-enolase cDNA [10] and subcloned in the bacterial
expression vector pGEX-3X (Pharmacia). The glutathione S-transfer-
ase^K-enolase fusion protein was overexpressed in Escherichia coli and
a⁄nity-puri¢ed by binding to glutathione-linked Sepharose beads ac-
cording to standard procedures.
In vitro transcription was carried out with 2 Wg of linearized pRCE-
NO1, pRCENO1-97 and pRCENO2 plasmids using a mRNA cap-
ping kit (Stratagene). In vitro translation was performed with a com-
mercially available rabbit reticulocyte lysate system according to the
instructions of the manufacturer (Promega), in the presence of
[35S]methionine (Amersham). Translation products were fractionated
on a 12% SDS^polyacrylamide gel and visualized by £uorography.
2.4. Immunoblot analysis
For immunoblot analysis total cell lysates (50 Wg) obtained by ex-
traction in 50 mM Tris^HCl pH 8.0, 150 mM NaCl, 1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, 0.4 mM phen-
ylmethylsulfonyl £uoride, 0.5 Wg/ml aprotinin, 1 Wg/ml leupeptin and
0.5 Wg/ml pepstatin, were resolved by electrophoresis on a 10% SDS-
polyacrylamide gel and electroblotted to a nitrocellulose membrane
(Hybond-C, Amersham). The membrane was incubated with anti-K-
enolase antiserum (1:5000) then with a secondary antibody conju-
gated to horseradish peroxidase (Amersham) (1:5000). The antigen^
antibody complexes were visualized by enhanced chemiluminescence
(Supersignal kit, Pierce).
2.5. Cell culture, transfection and luciferase assay
Human cervical carcinoma (HeLa), simian embryo kidney (COS-7)
and the human histiocytic lymphoma (U-937) cell lines were obtained
from the American Type Culture Collection (USA). The SV40-trans-
formed human ¢broblast (PAF), the human lymphoblastoid
(GM1500), the Burkitt’s lymphoma (Daudi) and the human T-cell
leukemia (Jurkat) cell lines were from laboratory stocks. Cells were
maintained in the following media containing 10% fetal calf serum,
100 U/ml penicillin and 100 Wg/ml streptomycin: RPMI 1640 (Sigma)
for U-937, PAF, GM1500, Daudi and Jurkat and Dulbecco’s modi-
¢ed Eagle’s medium (DMEM, Sigma) for HeLa and COS-7. Transient
transfection experiments were performed using FuGENE-6 transfec-
tion reagent according to the instructions of the manufacturer
(Roche). Brie£y, 1.5U105 cells were plated per 35 mm dish and trans-
fected with 1 Wg of pGL-cmp reporter vector, 0.01^1 Wg of one of the
pRC/CMV e¡ector vectors and 0.2 Wg of pRL-CMV vector (Prom-
ega), to monitor transfection e⁄ciency. Forty-eight hours after trans-
fection cells were harvested and cell lysates prepared in Passive Lu-
ciferase Bu¡er (Promega). The ¢re£y and Renilla luciferase assays
were performed using the Dual-Luciferase Reporter Assay System
(Promega) and luciferase activity measured with a TD-20/20 lumin-
ometer (Turner Design) equipped with an automatic dual injector
system.
For visualization of GFP by £uorescence, COS-7 cells were plated
on 35 mm tissue culture dishes containing glass coverslips and trans-
fected with 1 Wg of the GFP expression plasmids as described above.
At 48 h post transfection the cells were washed once in phosphate-
bu¡ered saline (PBS), ¢xed with 4% paraformaldehyde in PBS for
20 min, followed by an additional rinse in PBS containing DAPI
and observed using a £uorescent microscope.
3. Results
3.1. The ENO1 gene product speci¢cally binds to the
c-myc P2 promoter
MBP-1 has been shown to bind to a DNA sequence that
contains the TATA box of the c-myc P2 promoter [7]. The
protein shares considerable homology at the amino acid level
with the glycolytic enzyme K-enolase. To investigate a possible
correlation between MBP-1 and the ENO1 gene product, EM-
SAs were performed using nuclear extracts from HeLa cells
and a 36 bp end-labeled oligonucleotide (MP2) containing the
binding site reported for MBP-1 [7]. Two major DNA^protein
complexes were observed (Fig. 1, lane 1). The formation of
the slower migrating complex was abolished by competition in
EMSAs with a 100-fold molar excess of unlabeled MP2 oli-
gonucleotide (Fig. 1, lanes 2 and 3), while it was not a¡ected
by the use of an unrelated oligonucleotide (Fig. 1, lanes 4 and
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5), con¢rming the speci¢city of the binding. This DNA^pro-
tein complex was speci¢cally supershifted when anti-K-enolase
antibodies [10] were added to the binding reaction (Fig. 1,
lane 6), while pre-immune serum had no detectable e¡ects
(Fig. 1, lane 7). Taken together, these results indicate that
the DNA^protein complex observed contains a polypeptide
immunologically related to K-enolase that is present in the
nucleus. Similar results were obtained using nuclear extracts
from di¡erent human cell lines indicating the ubiquity of this
K-enolase-related protein (data not shown). To further inves-
tigate the identity of the enolase-related polypeptide present in
the complex, a GST^K-enolase fusion protein puri¢ed from
bacterial lysates was used in EMSAs. As shown in Fig. 1B the
recombinant K-enolase speci¢cally binds the MBP-1 consensus
(Fig. 1B, lane 1) as assessed by competition with an excess of
unlabeled MP2 oligonucleotide (Fig. 1B, lanes 2 and 3) and
the formation of a supershifted DNA^protein complex follow-
ing addition of anti-K-enolase antibodies (Fig. 1B, lanes 4 and
5). The presence of two di¡erently retarded complexes is due
to partial degradation of the puri¢ed GST^K-enolase protein,
as established by SDS-polyacrylamide gel and Western blot
with anti-K-enolase antibodies (data not shown). These data
indicate the capability of K-enolase to bind to the c-myc P2
promoter.
3.2. K-Enolase mRNA encodes two alternatively translated
polypeptides
Alignment of the amino acid sequence of K-enolase and
MBP-1 indicated that the MBP-1 initiator methionine corre-
sponds to a methionine at position 97 in K-enolase (Met-97).
This methionine is encoded by an AUG codon that is en-
closed in a good consensus for translation initiation [22] and
is conserved in all the K-enolase isoforms isolated from di¡er-
ent species, while it is absent in the L-enolase and Q-enolase
isoforms, although the three isoforms share more than 90%
similarity at the amino acid level in the same species [23]. In
order to establish if this methionine could represent an alter-
native translation start site the entire coding region of K-eno-
lase (ENO1) (aa 1^433), a partial cDNA lacking the nucleo-
tides encoding the ¢rst 96 amino acids of K-enolase (ENO1^
97) (aa 97^433) and the entire coding region of the Q-enolase
(ENO2) (aa 1^433) were cloned in the mammalian expression
vector pRC/CMV. The resulting plasmids were linearized and
in vitro transcribed and translated. Two translated products
were detected in the translation mixture programmed with
ENO1 mRNA (Fig. 2A, lane 1), the major product was a
polypeptide migrating with an apparent molecular mass of
48 kDa, corresponding to the entire K-enolase protein, the
minor product was a polypeptide migrating with an apparent
molecular mass of 37 kDa. A unique product migrating as a
37 kDa polypeptide was obtained in the translation mixture
programmed with ENO1-97 (Fig. 2A, lane 2), whereas a sin-
gle 48 kDa polypeptide was obtained with ENO2 (Fig. 2A,
lane 3) that has a leucine UUG codon (leucine) instead of a
AUG codon (methionine) at position 97. Incubation of the
translation mixtures at room temperature for increasing
Fig. 1. EMSA analysis of endogenous nuclear proteins and recombi-
nant GST^K-enolase. A: A labeled oligonucleotide (MP2) contain-
ing the MBP-1 binding site was incubated with nuclear extracts
(5 Wg) from HeLa cells (lanes 1^7). For competition in the EMSA a
100- and 200-fold molar excess of unlabeled MP2 oligonucleotide or
an unrelated oligonucleotide was added to the binding reaction mix-
ture. Addition of anti-K-enolase antibodies results in a supershift of
the slowly migrating speci¢c complex, while pre-immune serum has
no e¡ect (lanes 6, 7). The position of speci¢c and non-speci¢c com-
plexes is indicated by large and small arrowheads, respectively. The
faster migrating complex is probably due to an uneven ion front as
detected in the absence of nuclear extract (lane 8). B: EMSA per-
formed with a⁄nity puri¢ed GST^K-enolase protein using a labeled
MP2 oligonucleotide as probe. Competition in EMSA (lanes 2, 4)
and antibody interference (lanes 4, 5) are as described above. The
formation of two speci¢c complexes, indicated by the large arrow-
heads, is due to partial degradation of the puri¢ed GST^K-enolase
protein.
Fig. 2. A: Analysis of in vitro translated proteins. In vitro tran-
scribed RNAs from the full-length K-enolase cDNA (ENO1), a par-
tial K-enolase cDNA starting from the AUG triplet encoding me-
thionine 97 (ENO1^97) and a full-length Q-enolase cDNA (ENO2)
were translated in a rabbit reticulocyte system and products resolved
on a SDS-polyacrylamide gel (12% acrylamide) as described in Sec-
tion 2. As negative control a translation mixture with no addition
of exogenous RNA (No RNA) was run on the same gel (lane 4).
Molecular size markers are indicated on the left. B: Western blot
analysis of total cell extracts. Lysates from di¡erent human cell lines
(indicated at the top) were resolved on an SDS-polyacrylamide gel
(10% acrylamide), transferred to nitrocellulose and the ¢lter incu-
bated with anti-K-enolase, as described in Section 2. Molecular size
markers are indicated on the left.
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lengths of time and subsequent Western blot excluded the
possibility that the 37 kDa polypeptide could arise from pro-
teolytic cleavage of the entire K-enolase protein (data not
shown). These results suggest that a bona ¢de internal trans-
lation site is present in the full-length K-enolase mRNA and
most likely corresponds to the AUG encoding Met-97 as sug-
gested by the detection of a protein with the expected molec-
ular mass of 37 kDa. Translation initiation from this internal
AUG codon is about 20-fold less e⁄cient than the translation
initiation obtained from the ¢rst AUG codon of the K-enolase
mRNA. We decided to investigate if an K-enolase related
peptide of 37 kDa is present in vivo in human cells expressing
K-enolase. Western blot of total protein extracts from di¡er-
ent human cell lines performed with anti-K-enolase antibodies
clearly indicates the existence of a 37 kDa protein immuno-
logically related to K-enolase whose relative amount to the
48 kDa K-enolase is consistent with what was observed in
the in vitro experiments (Fig. 2B).
3.3. K-Enolase acts as a repressor of the c-myc promoter
transcriptional activity
To address the question if K-enolase and/or the related
37 kDa protein, encoded by the same mRNA but resulting
by translation initiation from an internal AUG codon, may
play a negative regulatory role in transcriptional regulation of
the c-myc gene, as has been reported for MBP-1 [24,25],
ENO1, ENO1^97 and ENO2 proteins were overexpressed in
transfection assays with a luciferase reporter plasmid contain-
ing the promoter region (nt 335^+650) of the human c-myc
gene. In di¡erent cell backgrounds, the expression of both
ENO1 and ENO1^97 resulted in a consistent reduction (55^
75%) of the luciferase activity relative to the activity detected
in cells transfected with the parental, insertless expression
vector (Fig. 3B). This reduction was not observed when
ENO2 was overexpressed in the same cell context and with
the same reporter plasmid (Fig. 3B). As a control, the ability
of each e¡ector plasmid to produce the corresponding pep-
tide(s) was assessed by Western blot of lysates from trans-
fected cells with anti-K- and anti-Q-enolase-speci¢c antibodies
(data not shown). The results obtained suggest that the re-
pression of luciferase activity consequent to overexpression of
the ENO1 gene product may be caused by the alternatively
translated 37 kDa protein encoded by this gene rather than by
K-enolase itself. This hypothesis is further supported by the
fact that in COS-7 cells cotransfected with lower amounts of
e¡ector plasmids (10^100 ng), a higher level of transcriptional
repression was observed in the cells overexpressing ENO1^97
than in cells overexpressing ENO1 (Fig. 3C) as if a threshold
amount of ENO1 mRNA was needed to produce enough
e¡ector protein. In conclusion, these experiments indicate
that a 37 kDa protein alternatively translated from the K-
enolase mRNA has the ability to repress transcription from
c-myc P2 promoter.
3.4. Subcellular localization of ENO-GFP chimeric proteins
overexpressed in COS-7 cells
To determine the subcellular localization of the proteins
6
Fig. 3. E¡ect of overexpression of enolase proteins on transcription-
al activation by the c-myc promoter. A: Schematic representation of
reporter and e¡ector plasmids used in transient transfection experi-
ments. pGL-cmp contains the c-myc promoter and part of the ¢rst
untranslated exon (black box) upstream of the ¢re£y luciferase gene
cloned in the pGL3 vector. E¡ectors a, b, c, and d correspond to
the expression vector pRC/CMV and recombinant constructs pRC-
ENO1, pRC-ENO1^97 and pRC-ENO2, respectively. B: Luciferase
assays of di¡erent cell lines (indicated at the bottom) cotransfected
with 1 Wg of the pGL-cmp reporter plasmid and 1 Wg of the insert-
less e¡ector plasmid (a), or plasmid expressing the full-length K-eno-
lase (b), or the amino-terminal shorter K-enolase (c), or the full-
length Q-enolase (d). C: Luciferase assays of COS-7 cells cotrans-
fected with 1 Wg of the pGL-cmp reporter plasmid and increasing
amounts (indicated at the bottom) of e¡ector plasmids. Luciferase
activities, corrected for di¡erences in transfection e⁄ciencies, are
compared with activity observed with the insertless e¡ector plasmid
that was arbitrarily set at 100%. The data are averages of at least
three independent experiments, and the error bars represent stand-
ard deviations.
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overexpressed in the cells, the GFP gene was fused in frame to
the 3P end of both the full-length cDNA encoding K-enolase
(pENO1^GFP) and the partial cDNA encoding the polypep-
tide spanning aa 97^433 (pENO1^97^GFP). The resulting fu-
sion proteins have a predicted molecular mass of 75 kDa and
64 kDa, respectively, which is above the size exclusion limit
(40^50 kDa) for passive di¡usion of protein through the nu-
clear pores [26]. The expression plasmids were transiently
transfected in COS-7 cells and after 48 h cells were treated
to visualize the GFP. Cells transfected with the plasmid ex-
pressing the GFP are homogeneously stained (Fig. 4a), since
GFP has a molecular mass of about 27 kDa and distributes
approximately equally between the cytoplasm and nucleus.
Di¡erent results were obtained when cells were transfected
with the two plasmids expressing the GFP fused to the entire
K-enolase protein (Fig. 4d) or to the polypeptide lacking the
¢rst 96 amino acids (Fig. 4g). The majority of the ENO1-GFP
chimera is retained in the cytoplasm, whereas the ENO1^97^
GFP chimeric protein is preferentially localized in the nuclei
of the transfected cells (Fig. 4e). These experiments indicate
that the deletion of the ¢rst 96 amino-terminal amino acids
from K-enolase results in a preferential nuclear localization of
the shorter polypeptide, compatible with its function of tran-
scriptional repressor of the c-myc promoter.
4. Discussion
The aim of this work was to test if the gene encoding the
glycolytic enzyme K-enolase, ENO1, could also encode MBP-
1, which acts as a transcriptional repressor of c-myc P2 pro-
moter activity. We have shown here that K-enolase and a
short form that initiates from an internal methionine, presum-
ably Met-97, have the ability to bind the TATA box region of
the c-myc P2 promoter and to reduce the expression of a lu-
ciferase reporter gene under the control of the c-myc promoter
in transient transfection experiments. All these features are
shared by MBP-1 [7,9]. Consistent with the high similarity
(about 97%) existing between MBP-1 and K-enolase cDNA
nucleotide sequences and with the colocalization of MBP-1
and ENO1 genes in the same region of human chromosome
1p36 [14,15], we propose that MBP-1 is a polypeptide alter-
natively translated from the full-length K-enolase mRNA.
This hypothesis is further supported by the fact that in vitro
transcription and translation of a full-length K-enolase cDNA
results in the production of two polypeptides with apparent
molecular weights of 48 kDa and 37 kDa respectively, while in
vitro transcription and translation of full-length Q-enolase
cDNA, whose coding region is more than 90% similar to
K-enolase but lacks of the AUG codon specifying Met-97,
results in the production of a single 48 kDa peptide. These
data indicate that the methionine at position 97 in the
K-enolase mRNA is the initiator methionine of the 37 kDa
polypeptide. Eukaryotic translation initiation usually occurs
at the ¢rst in-frame AUG codon that is in the optimal context
[22], however, leaky scanning may produce more than one
protein from a single mRNA, and in many instances the dif-
ferentially translated products have di¡erent subcellular fates.
For example, alternative initiation of translation determines
cytoplasmic or nuclear localization of bFGF [27], as well as of
the FGF-related protein Int-2 [28] and the prostatic protein
probasin [29]. The data presented here indicate that the two
products encoded by the ENO1 gene can have a di¡erent
function and subcellular localization. Most of the K-enolase
protein translated from the ¢rst AUG is present in the cyto-
plasm, but a consistent proportion of the shorter products
initiated at the internal AUG codon is diverted to the nucleus.
Enolase is a glycolytic enzyme and consistent with its primary
function it is predominantly localized in the cytoplasm where
it can be free or associated with the cytoskeleton with other
glycolytic enzymes [30]. Although nothing is known about the
domains of the protein responsible for the interactions with
the cytoskeleton, we can speculate that this signal is localized
within the ¢rst 96 amino acids of the protein and that the lack
of these amino acids in the 37 kDa peptide might determine
its translocation into the nucleus. Whether this translocation
is directly controlled by a non-canonical nuclear localization
signal or whether it is an indirect response remains to be
determined. Furthermore, it is possible that a preferential
translation of the 37 kDa products is linked to the di¡eren-
tiation stage of some cell types and regulated by an internal
ribosomal entry site (IRES), as has been reported for PDGF2/
c-sis mRNA [31]. A preliminary computer-assisted analysis
predicts structural features within the 5P coding region of
Fig. 4. Localization of ENO1^GFP chimeric proteins. COS-7 cells
were transiently transfected with the pEGFP-N1 expression plasmid,
encoding the wild-type GFP (a, b and c), the pENO1^GFP, encod-
ing the entire K-enolase^GFP (d, e and f), and the pENO1^97^
GFP, encoding the amino-terminal deleted K-enolase^GFP (g, h and
i), as reported in Section 2. Forty eight hours post-transfection cells
were ¢xed, counterstained with DAPI and visualized using a epi-
£uorescence equipped microscope for GFP staining (a, d and g) or
DAPI staining (b, e and h) or by phase contrast (c, f, and i). White
arrowheads in b, e and h indicate nuclei of transfected cells.
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the K-enolase mRNA that are common to known IRES ele-
ments [32].
It has been reported that other glycolytic enzymes may be
involved in a variety of cellular events in addition to their
primary catalytic role [33,34], such as GAPDH, which has
been found in the nucleus of certain cell types [35] and has
been shown to bind DNA [36]. Several other functions have
been reported for K-enolase: it is a heat shock protein in yeast
[37], it has been identi¢ed as the eye lens crystallin d in reptiles
and birds [38], it has been described as a component of the
centrosome in HeLa cells [39], it functions as a plasminogen
receptor in human peripheral blood cells [16], it is one of the
hypoxia-inducible proteins in human cells [40], an immuno-
dominant antigen in Candida albicans [41], and it has even
been identi¢ed as toxin B in Clostridium di⁄cile [42]. This
report indicates an additional functional role for K-enolase
carried out by an alternatively translated product whose struc-
tural and functional characteristics strongly support its iden-
tity with MBP-1. Recently it has been shown that the c-myc
downregulatory activity of MBP-1 resides in two hydrophobic
domains located in the amino- and in the carboxy-terminal
portion of the protein [25], both domains are present in the
37 kDa alternatively translated product of the K-enolase gene.
The gene encoding K-enolase (ENO1) maps to a region of
human chromosome 1 (1p35^p36) that is often deleted in
several human malignancies, including neuroblastoma, mela-
noma, pheochromocytoma, and carcinomas of the breast, liv-
er and colon [43]. Tumor-speci¢c deletions of distal 1p predict
the presence of one or more tumor suppressor loci in this
region. The ¢nding that a transcriptional repressor of the
c-myc oncogene is an alternatively translated product of the
ENO1 gene makes ENO1 a potential candidate for tumor
suppressor. This hypothesis is supported by the observations
that overexpression of MBP-1 induces loss of anchorage-in-
dependent growth and suppresses tumor formation in athymic
nude mice of human breast carcinoma cells [44], as well as
inducing cell death in murine ¢broblasts [8].
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